Cargando…

Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study

INTRODUCTION: The objective of the study was to compare compliance and acceptability of a new auto-injector (AI) versus syringe for administration of methotrexate (MTX) in patients with rheumatoid arthritis (RA). METHODS: We conducted a randomized, open-label, parallel group study comparing AI to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraux, Alain, Hudry, Christophe, Zinovieva, Elena, Herman-Demars, Hélène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393262/
https://www.ncbi.nlm.nih.gov/pubmed/30547379
http://dx.doi.org/10.1007/s40744-018-0134-2
_version_ 1783398648054284288
author Saraux, Alain
Hudry, Christophe
Zinovieva, Elena
Herman-Demars, Hélène
author_facet Saraux, Alain
Hudry, Christophe
Zinovieva, Elena
Herman-Demars, Hélène
author_sort Saraux, Alain
collection PubMed
description INTRODUCTION: The objective of the study was to compare compliance and acceptability of a new auto-injector (AI) versus syringe for administration of methotrexate (MTX) in patients with rheumatoid arthritis (RA). METHODS: We conducted a randomized, open-label, parallel group study comparing AI to pre-filled syringe (PFS). Adult patients with RA (ACR/EULAR 2010) receiving MTX (orally or by injection) for at least 3 months were allocated to AI or PFS for 6 months and then were allocated to AI for 6 further months. Two co-primary endpoints were defined at M6: percentage of patients with compliance at least 80%; change in functional capacity assessed by Health Assessment Questionnaire (HAQ). Secondary endpoints included quality of life (RaQoL), RA activity (DAS28), and acceptability. Local safety at injection site was assessed at each visit. RESULTS: Two-hundred and sixty-five patients were randomized. The main analysis was conducted on per protocol set (99 AI and 98 PFS). Compliance was 96.2% in AI and 98.9% in PFS. Good complier rates were 89.9% and 94.9%, thus a difference of − 5.0% (− 18.9%; 8.9%). HAQ remained stable in both groups. No difference was found on RaQoL, change in RA activity, and safety profile. Autonomy, acceptability, and patient satisfaction were better with AI, and patients having had the experience of both AI and PFS preferred AI (p < 0.001). CONCLUSIONS: Although this study did not demonstrate non-inferiority of AI versus PFS, compliance was excellent in the two groups, and AI, which was preferred by patients, is a valuable alternative to PFS for administration of MTX. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02553018. FUNDING: Nordic Pharma SAS.
format Online
Article
Text
id pubmed-6393262
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-63932622019-03-18 Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study Saraux, Alain Hudry, Christophe Zinovieva, Elena Herman-Demars, Hélène Rheumatol Ther Original Research INTRODUCTION: The objective of the study was to compare compliance and acceptability of a new auto-injector (AI) versus syringe for administration of methotrexate (MTX) in patients with rheumatoid arthritis (RA). METHODS: We conducted a randomized, open-label, parallel group study comparing AI to pre-filled syringe (PFS). Adult patients with RA (ACR/EULAR 2010) receiving MTX (orally or by injection) for at least 3 months were allocated to AI or PFS for 6 months and then were allocated to AI for 6 further months. Two co-primary endpoints were defined at M6: percentage of patients with compliance at least 80%; change in functional capacity assessed by Health Assessment Questionnaire (HAQ). Secondary endpoints included quality of life (RaQoL), RA activity (DAS28), and acceptability. Local safety at injection site was assessed at each visit. RESULTS: Two-hundred and sixty-five patients were randomized. The main analysis was conducted on per protocol set (99 AI and 98 PFS). Compliance was 96.2% in AI and 98.9% in PFS. Good complier rates were 89.9% and 94.9%, thus a difference of − 5.0% (− 18.9%; 8.9%). HAQ remained stable in both groups. No difference was found on RaQoL, change in RA activity, and safety profile. Autonomy, acceptability, and patient satisfaction were better with AI, and patients having had the experience of both AI and PFS preferred AI (p < 0.001). CONCLUSIONS: Although this study did not demonstrate non-inferiority of AI versus PFS, compliance was excellent in the two groups, and AI, which was preferred by patients, is a valuable alternative to PFS for administration of MTX. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02553018. FUNDING: Nordic Pharma SAS. Springer Healthcare 2018-12-13 /pmc/articles/PMC6393262/ /pubmed/30547379 http://dx.doi.org/10.1007/s40744-018-0134-2 Text en © The Author(s) 2018 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Saraux, Alain
Hudry, Christophe
Zinovieva, Elena
Herman-Demars, Hélène
Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study
title Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study
title_full Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study
title_fullStr Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study
title_full_unstemmed Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study
title_short Use of Auto-Injector for Methotrexate Subcutaneous Self-Injections: High Satisfaction Level and Good Compliance in SELF-I Study, a Randomized, Open-Label, Parallel Group Study
title_sort use of auto-injector for methotrexate subcutaneous self-injections: high satisfaction level and good compliance in self-i study, a randomized, open-label, parallel group study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393262/
https://www.ncbi.nlm.nih.gov/pubmed/30547379
http://dx.doi.org/10.1007/s40744-018-0134-2
work_keys_str_mv AT sarauxalain useofautoinjectorformethotrexatesubcutaneousselfinjectionshighsatisfactionlevelandgoodcomplianceinselfistudyarandomizedopenlabelparallelgroupstudy
AT hudrychristophe useofautoinjectorformethotrexatesubcutaneousselfinjectionshighsatisfactionlevelandgoodcomplianceinselfistudyarandomizedopenlabelparallelgroupstudy
AT zinovievaelena useofautoinjectorformethotrexatesubcutaneousselfinjectionshighsatisfactionlevelandgoodcomplianceinselfistudyarandomizedopenlabelparallelgroupstudy
AT hermandemarshelene useofautoinjectorformethotrexatesubcutaneousselfinjectionshighsatisfactionlevelandgoodcomplianceinselfistudyarandomizedopenlabelparallelgroupstudy
AT useofautoinjectorformethotrexatesubcutaneousselfinjectionshighsatisfactionlevelandgoodcomplianceinselfistudyarandomizedopenlabelparallelgroupstudy